Send to Kindle
The coronavirus vaccine developed by Pfizer and BioNTech appears to protect 94% of adults over 65 years old.
More data released from their ongoing phase three trial suggests it works equally well in people of all ages, races and ethnicities.
The companies say they will now apply for authorisation for emergency use of the jab in the US.
The findings are based on two doses given to more than 41,000 people around the world.
Last week, Pfizer and BioNTech published preliminary data showing the vaccine offered 90% protection against Covid-19 and there were no safety concerns.
This was followed by impressive data on another vaccine, made by US company Moderna, suggesting nearly 95% protection.
Wednesday's data from Pfizer and BioNTech suggests the vaccine is 95% effective, based on 170 cases of Covid-19 developing in volunteers - just eight were in the group given the vaccine, suggesting it offers good protection.
The rest of the cases were in the placebo group given a dummy jab.
Although the full trial data has yet to be published, the companies say there have been no serious safety concerns. But they did notice headaches and fatigue in about 2% of volunteers given the vaccine.
In the trial, 42% of all participants are from diverse ethnic backgrounds and 41% are aged between 56 and 85 years old.
The trial, which is testing people at 150 sites in the US, Germany, Turkey, South Africa, Brazil and Argentina, will collect data on the safety and efficacy of the vaccine for another two years./BBC
We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!
European prosecutors are delving into allegations of corruption surrounding the COVID-19 vaccine negotiations between European Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla
The European Commission has granted approval for the Nuvaxovid XBB.1.5-adapted COVID-19 vaccine, a groundbreaking step in the fight against the ever-evolving pandemic
Katalin Kariko and Drew Weissman won the Nobel Prize in Physiology or Medicine, reported the Nobelprize.org website
80,640 doses of the new vaccine against Omicron subvariant XBB 1.5 have already been delivered to Bulgaria
Pharmaceutical giant Pfizer said it plans a cost-cutting operation if its co-developed with BioTech COVID-19 vaccine and antiviral treatment for the coronavirus continue to underperform in the coming months due to falling demand
It is dangerous that people do not want to vaccinate their children
In response to the recent deaths of two newborns due to whooping cough, the Ministry of Health in Bulgaria has implemented measures to curb the spread of the disease
The World Health Organization (WHO) has issued a stark warning regarding the spread of bird flu (H5N1) to various species, including humans, expressing deep concern over its impact and potential consequences
Data from a recent global poll conducted by the world association "Gallup International" represent the diverse perceptions surrounding the threat posed by the coronavirus pandemic
The National Center for Infectious and Parasitic Diseases in Bulgaria has confirmed the country's first case of measles, sparking concerns about potential outbreaks.
While assurances of salary boosts for nurses employed in kindergartens and nurseries have been made recently, the fundamental challenges endure, plunging the sector into a precarious situation
A new report of a gas leak in Karnobat has sparked concern among residents and authorities, as emergency services rush to address the situation
UN Happiness Report: Bulgaria's Astonishing Leap in Rankings
Bulgaria: 3 Regions With Lowest Life Expectancy - EU Report 2022
